Table 5.

Summary table of pediatric and adult therapeutic approaches in HL, BL, DLBCL, PMBCL, and ALCL

	Pediatric approach	Adult approach
HL
Stage I/II (non-bulky)	ABVE × 2–4 ± RT; VAMP × 4 ± RT; OEPA × 2 ± RT	ABVD × 4–6 with risk-adapted use of RT
Stage I/II (bulky)	ABVE-PC × 4 ± RT; OEPA × 2, plus COPDAC × 2 ± RT	ABVD × 4–6 plus RT in most cases
Stage III/IV	ABVE-PC × 4–5 plus RT in most cases; OEPA × 2, plus COPDAC × 4 ± RT	ABVD × 6
BL
Low risk	COPAD × 2	R-CODOX-M × 3, DA-EPOCH-R, or rituximab, or R-hyper-CVAD
High risk	FAB LMB96 protocol + rituximab*	R-CODOX-M/IVAC or R-hyper-CVAD
DLBCL	Burkitt-like therapy	R-CHOP × 6
PMBCL	DA-EPOCH-R × 6	DA-EPOCH-R × 6
ALCL	ALCL 99 protocol†	CHOEP × 6

CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; R-CODOX-M, rituximab plus cyclophosphamide, vincristine, and doxorubicin-methotrexate; R-CODOX-M/IVAC,rituximab plus cyclophosphamide, vincristine, and doxorubicin-methotrexate/ifosfamide, etoposide, and cytarabine; R-hyper-CVAD, rituximab plus hyper-CVAD.

^*R-CHOP (rituximab plus cyclophosphamide, vincristine, and prednisone) prophase → 2 cycles of induction with R-COPADM × 2 → 2 cycles of maintenance with rituximab plus CYM plus intrathecal chemotherapy.

^†Cyclophosphamide-dexamethasone prophase followed by 6 alternating cycles of course A (dexamethasone, high-dose methotrexate, ifosfamide, cytarabine, and etoposide) and course B (dexamethasone, high-dose methotrexate, cyclophosphamide, and doxorubicin) chemotherapy.